<DOC>
	<DOCNO>NCT01298193</DOCNO>
	<brief_summary>This prospective , multicenter , open label , non-comparative trial Spain . The primary objective study determine complete response , define vomit use rescue treatment , woman early-stage breast cancer treat one cycle Docetaxel-Cyclophosphamide active therapy prevention CINV ( Chemotherapy-induced nausea vomit ) day 1 , 5-HT3 antagonist plus 3 day dexamethasone . A second step ( efficacy phase ) design examine efficacy tolerability aprepitant second cycle among patient fail previous CINV prevention treatment . The study focus early-stage chemonaïve breast cancer patient receive docetaxel-cyclophosphamide 5-HT3 antagonist plus dexamethasone CINV prevention . The CINV incidence patient evaluate first cycle . All refractory patient , ask participate second phase , aprepitant day 1 , 2 3 add antiemetic regimen . Assuming drop 5 % , 212 patient include study . It anticipate around 48 patient enter efficacy phase . The duration study , first patient visit last patient visit approximately 21 month .</brief_summary>
	<brief_title>Incidence Chemotherapy-Induced Nausea Vomiting ( CINV ) Associated With Docetaxel-Cyclophosphamide Regimen Early Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>1 . Female patient ≥ 18 year age . 2 . Patient histological confirm earlystage ( I III ) breast cancer . 3 . Patient able understand study procedure agree participate study give write informed consent . 4 . Patient naïve moderate highly emetogenic chemotherapy per Hesketh criterion ( see Appendix 7.1 ) . 5 . Patient schedule receive chemotherapy DocetaxelCyclophosphamide ( Docetaxel 75mg/m2 Cyclophosphamide 600mg/m2 ) administer every 21 day . 6 . Patient predict life expectancy ≥ 4 month . 7 . Functional State 01 ECOG Scale ( see Appendix 12.2 ) . 8 . Patient adequate organ function include follow : Bone marrow reserve : Absolute Neutrophil Count &gt; 1500/mm3 WBC count &gt; 3000/mm3 ; Platelet Count &gt; 100.000/mm3 Hepatic : AST ( aspartate transaminase ) &lt; 2.5 x upper limit normal ; ALT ( alanine transaminase ) &lt; 2.5 x upper limit normal ; Bilirubin within normal limit . Renal : Creatinine &lt; 1.5 x upper limit normal . 9 . Premenopausal female patient must demonstrate negative serum and/or urine pregnancy test within 3 day study drug administration , agree use doublebarrier form contraception least 14 day prior , throughout least 14 day follow last dose study medication . Women take oral contraceptive agent must agree add barrier form contraception . Abstinence also consider acceptable form contraception . ( Note : A female patient reproductive potential eligible without require use contraception . A female patient reproductive potential define one either : 1 ) reach natural menopause ( defined 6 month spontaneous amenorrhea serum FSH level postmenopausal range determine laboratory , 12 month spontaneous amenorrhea ) ; 2 ) 6 week post surgical bilateral oophorectomy without hysterectomy ; 3 ) bilateral tubal ligation . ) 10 . Patient able read , understand complete study questionnaire . 1 . Patient schedule receive chemotherapy treatment different DocetaxelCyclophosphamide chemotherapy . 2 . Patient receive receive radiation therapy abdomen , chest pelvis month prior study enter . 3 . Patient vomit 24 hour prior Treatment Day 1 . 4 . Patient history treatment emetogenic chemotherapy moderate high level per Hesketh ( see Appendix 7.1 ) . 5 . Patient active infection ( e.g. , pneumonia ) uncontrolled disease ( e.g. , diabetic ketoacidosis , gastrointestinal obstruction ) except malignancy , opinion investigator , might confound result study pose unwarranted risk . 6 . Patient currently use illicit drug , include marijuana , current evidence alcohol abuse determine investigator . 7 . Patient mentally incapacitate significant emotional psychiatric disorder , opinion investigator , precludes study entry . 8 . Patient history illness , opinion investigator , might confound result study pose unwarranted risk . 9 . Patient history hypersensitivity aprepitant , 5HT3 antagonist , dexamethasone . 10 . Patient pregnant breast feeding . 11 . Patient participate study aprepitant take non approve ( investigational ) drug within last 4 week . 12 . Patient take systemic corticosteroid therapy dose ; topical inhale corticosteroid permit . 13 . Patient taking , take within 28 day Day 1 cycle 2 ( cycle patient start take aprepitant ) follow CYP3A4 inducer : phenytoin carbamazepine barbiturates rifampicin rifabutin St. John 's Wort 14 . Patient taking , take within 7 day Day 1 cycle 2 follow CYP3A4 substrate : terfenadine cisapride astemizole pimozide 15 . Patient taking , take within 7 day Day 1 cycle 2 follow CYP3A4 inhibitor : clarithromycin ketoconazole , itraconazole 16 . Patient take antiemetic within 48 hour Day 1 cycle 2 . Prohibited antiemetic include : 5HT3 antagonist ( ondansetron , granisetron , dolasetron , tropisetron palonosetron ) phenothiazine ( e.g. , prochlorperazine , fluphenazine , perphenazine , thiethylperazine , chlorpromazine ) butyrophenones ( e.g. , haloperidol droperidol ) benzamides ( e.g. , metoclopramide alizapride ) domperidone cannabinoids herbal therapy potential antiemetic property scopolamine cyclizine 17 . Patient use benzodiazepine opiate , except single daily dos triazolam , temazepam midazolam 48 hour prior Day 1 cycle 2 . Continuation chronic benzodiazepine opiate therapy permit provide iniciated least 48 hour enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Early-stage breast cancer patient</keyword>
</DOC>